作者: Pedrazzi, João Francisco Cordeiro ; Oliveira-Lima, Onésia Cristina ; Carvalho, Gustavo Almeida ; Pinto, Mauro Cunha Xavier ; Silva-Amaral, Danyelle ; Schildknecht, Stefan ; Leist, Marcel ; Del-Bel, Elaine Aparecida ; da Rocha, André Luís Batista ; Birbrair, Alexander ; Menegatti, Ricardo ; Chiareli, Raphaela Almeida ; Lião, Luciano Morais ; de Souza-Fagundes, Elaine Maria ; Gomez, Renato Santiago

The glutamatergic hypothesis of schizophrenia suggests a correlation between NMDA receptor hypofunction and negative psychotic symptoms. It has been observed that the expression of the proline transporter (PROT) in the central nervous system (CNS) is associated with glutamatergic neurotransmission, as L-proline has the capacity to activate and modulate AMPA and NMDA receptors. In this study, we aimed to investigate whether inhibition of proline transporters could enhance glutamatergic neurotransmission and potentially exhibit antipsychotic effects in an experimental schizophrenia model. Using molecular dynamics analysis in silico, we validated an innovative PROT inhibitor, LQFM215. We quantified the cytotoxicity of LQFM215 in the Lund human mesencephalic cell line (LUHMES). Subsequently, we employed the ketamine-induced psychosis model to evaluate the antipsychotic potential of the inhibitor, employing behavioral tests including open-field, three-chamber interaction, and prepulse inhibition (PPI). Our results demonstrate that LQFM215, at pharmacologically active concentrations, exhibited negligible neurotoxicity when astrocytes were co-cultured with neurons. In the ketamine-induced psychosis model, LQFM215 effectively reduced hyperlocomotion and enhanced social interaction in a three-chamber social approach task across all administered doses. Moreover, the compound successfully prevented the ketamine-induced disruption of sensorimotor gating in the PPI test at all tested doses. Overall, these findings suggest that PROT inhibition could serve as a potential therapeutic target for managing symptoms of schizophrenia model.

2023-04-01·Pharmacological Reports

L-proline transporter inhibitor (LQFM215) promotes neuroprotection in ischemic stroke

Article

作者: da Rocha, André Luís Batista ; de Carvalho, Flávio Silva ; Lião, Luciano Morais ; Carvalho, Gustavo Almeida ; Vaz, Boniek Gontijo ; Noël, François ; Marques, Bruno Lemes ; Menegatti, Ricardo ; Verli, Hugo ; Silva, Rafaela Ribeiro ; de Souza Gil, Eric ; Pinto, Mauro Cunha Xavier ; Ahmad, Shabir ; Chiareli, Raphaela Almeida ; Parreira, Ricardo Cambraia

BACKGROUNDL-proline transporter (PROT/SLC6A7) is closely associated with glutamatergic neurotransmission, where L-proline modulates the NMDA receptor (NMDAR) function. NMDAR-mediated excitotoxicity is a primary cause of neuronal death following stroke, which is triggered by the uncontrolled release of glutamate during the ischemic process. After ischemic stroke, L-proline levels show a reduction in the plasma, but high circulating levels of this molecule indicate good functional recovery. This work aimed to produce new PROT inhibitors and explore their effects on ischemic stroke.METHODSInitially, we built a three-dimensional model of the PROT protein and run a molecular docking with the newly designed compounds (LQFM215, LQFM216, and LQFM217). Then, we synthesized new PROT inhibitors by molecular hybridization, and proline uptake was measured in ex vivo and in vivo models. The behavioral characterization of the treated mice was performed by the open-field test, elevated plus-maze, Y-maze, and forced swimming test. We used the permanent middle cerebral artery occlusion (MCAO) model to study the ischemic stroke damage and analyzed the motor impairment with limb clasping or cylinder tests.RESULTSLQFM215 inhibited proline uptake in hippocampal synaptosomes, and the LQFM215 treatment reduced proline levels in the mouse hippocampus. LQFM215 reduced the locomotor and exploratory activity in mice and did not show any anxiety-related or working memory impairments. In the MCAO model, LQFM215 pre-treatment and treatment reduced the infarcted area and reduced motor impairments in the cylinder test and limb clasping.CONCLUSIONSThis dataset suggests that the new compounds inhibit cerebral L-proline uptake and that LQFM215 promotes neuroprotection and neuro-repair in the acute ischemic stroke model.

100 项与 LQFM215 相关的药物交易

登录后查看更多信息